Patrick Forde: ALINA adjuvant alectinib vs chemo for ALK post resected lung cancer

Quoting Patrick Forde, Co-Director of the Division of Upper Aerodigestive Malignancies Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, on X/Twitter:

ALINA adjuvant alectinib vs chemo for ALK post resected lung cancer. Again unfortunate re-data leak but a sneak peek looks good. HR 0.24 favoring alectinib 30% improvement in DFS at 3 years. Adjuvant chemo followed by alectinib is likely the path forward.

Source: Patrick Forde/Twitter